Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Inclusion Criteria: * Female patients with histologic proven, corebiopsied, invasive ductal adenocarcinoma of the breast \>2 cm in size and of any N stage (clinical and/or radiological T-stage \> T1, including T4d), scheduled to receive preoperative chemotherapy. * Age 18-70 years * ECOG performance-status ≤1 * No prior or current neoplasm except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix * No distant disease/secondary carcinoma * Normal cardiac function * Results of the following assessments at the time of inclusion must be available: 1. bilateral Mammography (before enrolment) 2. histology 3. grading 4. hormone-receptor-status 5. HER2 status negative (is defined as FISH/CISH negative or IHC0 or IHC1+, or IHC2+ and FISH/CISH negative) * Laboratory requirements (within 1 week before enrolment): 1. Hematology: Neutrophils ≥ 1.5 x 109/l, Platelets ≥ 100 x 109/l, Hemoglobin\>11 g/dl 2. Hepatic function: Total bilirubin \< 1 x ULN, SGOT and SGPT \< 1.5 x ULN, Alkaline phosphatases \< 1.5 x ULN. In case of abnormal values, the liver function tests have to be repeated within 3 days before study treatment. 3. Renal function: Creatinine \< 1 x ULN 4. Urinalysis: Urine dipstick of proteinuria \< 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \<1 g of protein / 24 hours. * Signed and dated Informed Consent before the start of specific protocol procedures * If of childbearing potential, negative pregnancy test Exclusion Criteria: * Cytological only confirmation of diagnosis * Lobular or other non-ductal types of breast cancer * Pregnant, or lactating patients; patients of childbearing potential must implement adequate contraceptive measures during study participation * Pre-existing motor or sensory neurotoxicity of a severity \> grade 2 by NCI-CTC AE * Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy) * Prior or concurrent systemic antitumor therapy * Evidence of wound healing complications, bone fracture, ulcer or the presence of clinically significant peripheral vascular disease * Clinically significant cardiac disease e.g. congestive heart failure. * Other serious illness or medical condition-uncontrolled hypertension or high risk uncontrolled arrythmias -history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent-active uncontrolled infection-unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of corticosteroids * Known hypersensitivity reaction to the compounds or incorporated substances. * Evidence of bleeding diathesis or coagulopathy * The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR, or appropriate monitoring test is within therapeutic limits and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization. Patients not receiving anti coagulant medication must have an INR ≤ 1.5 an aPTT ≤ 1.5 x ULN within 7 days of randomization. * Ongoing treatment with aspirin (\> 325mg / day) or other medications known to predispose to gastrointestinal ulceration. * Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment. * Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion * Treatment with an investigational drug within 30 days prior to study entry. * Legally incapacitated and/or other circumstances which make it undesirable for the subject to understand the nature, meaning and consequences of the clinical study